4.8 Article

Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2024055118

Keywords

PRMT5i resistance; STMN2; collateral sensitivity

Funding

  1. National Cancer Institute [P30-CA14051, PO1 CA42063, T32 CA009216, R01 CA233477-01]
  2. Koch Institute Frontier Research Program
  3. Koch Institute Director's Anonymous Discretionary Research Funds
  4. Ludwig Center at the Massachusetts Institute of Technology (MIT)
  5. MIT Center for Precision Cancer Medicine
  6. Charles W. and Jennifer C. Johnson Clinical Investigator Award
  7. NIH [GM007287]
  8. NSF Graduate Research Fellowship
  9. David H. Koch Fellowship in Cancer Research

Ask authors/readers for more resources

Epigenetic regulators are crucial in cancer treatment, but resistance mechanisms to their inhibition are not well understood. A study on PRMT5 inhibitors in lung adenocarcinoma cell lines revealed a drug-induced transcriptional switch leading to rapid resistance. The resistant state, stabilized across LUAD variants, also showed vulnerabilities to other chemotherapeutics like paclitaxel, due to the presence of STMN2. This gene was found to be essential for both PRMT5 inhibition resistance and sensitivity to paclitaxel, highlighting a potential therapeutic combination for cancer treatment.
Epigenetic regulators play key roles in cancer and are increasingly being targeted for treatment. However, for many, little is known about mechanisms of resistance to the inhibition of these regulators. We have generated a model of resistance to inhibitors of protein arginine methyltransferase 5 (PRMT5). This study was conducted in Kras(G12D);Tp53-null lung adenocarcinoma (LUAD) cell lines. Resistance to PRMT5 inhibitors (PRMT5i) arose rapidly, and barcoding experiments showed that this resulted from a druginduced transcriptional state switch, not selection of a preexisting population. This resistant state is both stable and conserved across variants arising from distinct LUAD lines. Moreover, it brought with it vulnerabilities to other chemotherapeutics, especially the taxane paclitaxel. This paclitaxel sensitivity depended on the presence of stathmin 2 (STMN2), a microtubule regulator that is specifically expressed in the resistant state. Remarkably, STMN2 was also essential for resistance to PRMT5 inhibition. Thus, a single gene is required for both acquisition of resistance to PRMT5i and collateral sensitivity to paclitaxel in our LUAD cells. Accordingly, the combination of PRMT5i and paclitaxel yielded potent and synergistic killing of the murine LUAD cells. Importantly, the synergy between PRMT5i and paclitaxel also extended to human cancer cell lines. Finally, analysis of The Cancer Genome Atlas patient data showed that high STMN2 levels correlate with complete regression of tumors in response to taxane treatment. Collectively, this study reveals a recurring mechanism of PRMT5i resistance in LUAD and identifies collateral sensitivities that have potential clinical relevance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available